Cartesian Therapeutics, Inc. Increase (Decrease) in Restricted Cash for Operating Activities
Cartesian Therapeutics, Inc. (RNAC) reported Increase (Decrease) in Restricted Cash for Operating Activities of -$689.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities · last filed 2018-03-15
- Cartesian Therapeutics, Inc. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-12-31 was $14.00K, a 96.53% decline year-over-year.
- Cartesian Therapeutics, Inc. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-09-30 was $1.00K.
- Cartesian Therapeutics, Inc. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-06-30 was -$707.00K.
- Cartesian Therapeutics, Inc. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-03-31 was $3.00K, a 99.83% decline year-over-year.
- Cartesian Therapeutics, Inc. increase (decrease) in restricted cash for operating activities for fiscal 2017 was -$689.00K.
- Cartesian Therapeutics, Inc. increase (decrease) in restricted cash for operating activities for fiscal 2016 was -$103.00K.
- Cartesian Therapeutics, Inc. increase (decrease) in restricted cash for operating activities for fiscal 2015 was -$977.00K, a 154.92% decline from fiscal 2014.
- Cartesian Therapeutics, Inc. increase (decrease) in restricted cash for operating activities for fiscal 2014 was $1.78M.
| Period end | Increase (Decrease) in Restricted Cash for Operating Activities 3 month | Increase (Decrease) in Restricted Cash for Operating Activities 6 month | Increase (Decrease) in Restricted Cash for Operating Activities 9 month | Increase (Decrease) in Restricted Cash for Operating Activities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $15.00K derived: sum of 2 quarters · filed 2018-03-15 | -$692.00K derived: sum of 3 quarters · filed 2018-03-15 | -$689.00K 10-K · filed 2018-03-15 |
| 2017-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$706.00K derived: sum of 2 quarters · filed 2017-11-07 | -$703.00K 10-Q · filed 2017-11-07 | -$299.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-06-30 | -$707.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | -$704.00K 10-Q · filed 2017-08-11 | -$300.00K derived: sum of 3 quarters · filed 2018-03-15 | -$2.16M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-03-31 | $3.00K 10-Q · filed 2017-05-11 | $407.00K derived: sum of 2 quarters · filed 2018-03-15 | -$1.45M derived: sum of 3 quarters · filed 2018-03-15 | -$1.85M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-12-31 | $404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$1.45M derived: sum of 2 quarters · filed 2018-03-15 | -$1.85M derived: sum of 3 quarters · filed 2018-03-15 | -$103.00K 10-K · filed 2018-03-15 |
| 2016-09-30 | -$1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$2.26M derived: sum of 2 quarters · filed 2017-11-07 | -$507.00K 10-Q · filed 2017-11-07 | -$96.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | -$401.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $1.35M 10-Q · filed 2017-08-11 | $1.76M derived: sum of 3 quarters · filed 2018-03-15 | $675.00K derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | $1.75M 10-Q · filed 2017-05-11 | $2.16M derived: sum of 2 quarters · filed 2018-03-15 | $1.08M derived: sum of 3 quarters · filed 2018-03-15 | |
| 2015-12-31 | $411.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$676.00K derived: sum of 2 quarters · filed 2018-03-15 | -$977.00K 10-K · filed 2018-03-15 | |
| 2015-09-30 | -$1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$1.39M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | -$301.00K 10-Q · filed 2016-08-09 | |||
| 2014-12-31 | $1.78M 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |